Program
RC148
A development code. Also written as “RC148 plus Telisotuzumab adizutecan”, “RC118(Dose 1) plus RC148(Dose 1)” and “RC118(Dose 1) plus RC148(Dose 2)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Colonic Neoplasms · Breast Neoplasms, led by RemeGen.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGen | 88 open or running | phase 3since Feb 10, 2026 | Aug 18, 2023 | May 12, 2027phase 3 · NCT07462143 |
- Named in abbvie’s own pipeline as
ABBV-1480 (RC148)
, phase 3, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2023First study: phase 2 study in Solid TumorFirst studyNCT06016062 · 221 planned · China
- Oct 13, 2024Phase 2 study in Breast NeoplasmsNCT06642545 · 40 planned · China
- Mar 5, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06883630 · 121 enrolled · China
- Feb 10, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07416474 · 574 planned · China
- Mar 4, 2026Phase 3 study in Colonic NeoplasmsNCT07462143 · 80 planned · China
- Sep 8, 2026Phase 3 study in Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic AlterationsNCT07829549 · 540 planned · China
- Oct 12, 2026Phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyNCT07895355 · 412 planned · China
- Nov 1, 2026Phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT07935369 · 680 planned · China
Ahead
- May 12, 2027Primary completion: phase 3 study in Colonic NeoplasmsNCT07462143
- Dec 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07416474
- Jul 2028Primary completion: phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyNCT07895355
- Apr 30, 2030Primary completion: phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT07935369
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07935369Advanced Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Not yet recruiting | Apr 30, 2030 | 680 |
| NCT07895355Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy · China | 2 | Not yet recruiting | Jul 2028 | 412 |
| NCT07829549Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations · China | 3 | Recruiting | Apr 2031 | 540 |
| NCT07462143Colonic Neoplasms · China | 3 | Recruiting | May 12, 2027 | 80 |
| NCT07416474Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Dec 31, 2027 | 574 |
| NCT06883630Carcinoma, Non-Small-Cell Lung · China | 1 | Active, not recruiting | Aug 31, 2026 | 121 |
| NCT06642545Breast Neoplasms · China | 2 | Recruiting | Oct 1, 2026 | 40 |
| NCT06016062Solid Tumor · China | 2 | Recruiting | Dec 31, 2025 | 221 |
How it is read
Names in the registry
- “RC148 plus Telisotuzumab adizutecan”, 4 entries
- “RC148”, 2 entries
- “RC118(Dose 1) plus RC148(Dose 1)”, 1 entry
- “RC118(Dose 1) plus RC148(Dose 2)”, 1 entry
- “RC118(Dose 2) plus RC148(Dose 1)”, 1 entry
Codes read as this program: RC148.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Colorectal Neoplasms, 1 study
- Colonic Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.